Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Examination of the genetic factors underlying the cognitive variability associated with neurofibromatosis type 1.

Ottenhoff MJ, Rietman AB, Mous SE, Plasschaert E, Gawehns D, Brems H, Oostenbrink R; ENCORE-NF1 Team, van Minkelen R, Nellist M, Schorry E, Legius E, Moll HA, Elgersma Y.

Genet Med. 2020 Feb 4. doi: 10.1038/s41436-020-0752-2. [Epub ahead of print]

PMID:
32015538
2.

An overview of health issues and development in a large clinical cohort of children with Angelman syndrome.

Bindels-de Heus KGCB, Mous SE, Ten Hooven-Radstaake M, van Iperen-Kolk BM, Navis C, Rietman AB, Ten Hoopen LW, Brooks AS; ENCORE Expertise Center for AS, Elgersma Y, Moll HA, de Wit MY.

Am J Med Genet A. 2020 Jan;182(1):53-63. doi: 10.1002/ajmg.a.61382. Epub 2019 Nov 15.

3.

Everolimus for the treatment of refractory seizures associated with tuberous sclerosis complex (TSC): current perspectives.

Overwater IE, Rietman AB, van Eeghen AM, de Wit MCY.

Ther Clin Risk Manag. 2019 Jul 26;15:951-955. doi: 10.2147/TCRM.S145630. eCollection 2019. Review.

4.

Omphalocele at school age: What do parents report? A call for long-term follow-up of complex omphalocele patients.

Hijkoop A, Rietman AB, Wijnen RMH, Tibboel D, Cohen-Overbeek TE, van Rosmalen J, IJsselstijn H.

Early Hum Dev. 2019 Oct;137:104830. doi: 10.1016/j.earlhumdev.2019.104830. Epub 2019 Jul 30.

PMID:
31374454
5.

Gastroschisis at school age: what do parents report?

Hijkoop A, Rietman AB, Wijnen RMH, Tibboel D, Cohen-Overbeek TE, van Rosmalen J, IJsselstijn H.

Eur J Pediatr. 2019 Sep;178(9):1405-1412. doi: 10.1007/s00431-019-03417-5. Epub 2019 Jul 19.

6.

A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex.

Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, van der Vaart T, Jansen FE, Elgersma Y, Moll HA, de Wit MY; ENCORE Expertise Centre for Neurodevelopmental Disorders.

Neurology. 2019 Jul 9;93(2):e200-e209. doi: 10.1212/WNL.0000000000007749. Epub 2019 Jun 19.

PMID:
31217257
7.

Pediatric Perceived Cognitive Functioning: Psychometric Properties and Normative Data of the Dutch Item Bank and Short Form.

Marchal JP, de Vries M, Conijn J, Rietman AB, IJsselstijn H, Tibboel D, Haverman L, Maurice-Stam H, Oostrom KJ, Grootenhuis MA.

J Int Neuropsychol Soc. 2019 Sep;25(8):845-856. doi: 10.1017/S1355617719000572. Epub 2019 Jun 10.

PMID:
31179957
8.

Worries and needs of adults and parents of adults with neurofibromatosis type 1.

Rietman AB, van Helden H, Both PH, Taal W, Legerstee JS, van Staa A, Moll HA, Oostenbrink R, van Eeghen AM.

Am J Med Genet A. 2018 May;176(5):1150-1160. doi: 10.1002/ajmg.a.38680.

9.

Working Memory Training Following Neonatal Critical Illness: A Randomized Controlled Trial.

Schiller RM, Madderom MJ, van Rosmalen J, van Heijst AFJ, de Blaauw I, Utens E, Rietman AB, Verhulst F, Tibboel D, White T, IJsselstijn H.

Crit Care Med. 2018 Jul;46(7):1158-1166. doi: 10.1097/CCM.0000000000003151.

PMID:
29624536
10.

Autism Spectrum Disorder in an Unselected Cohort of Children with Neurofibromatosis Type 1 (NF1).

Eijk S, Mous SE, Dieleman GC, Dierckx B, Rietman AB, de Nijs PFA, Ten Hoopen LW, van Minkelen R, Elgersma Y, Catsman-Berrevoets CE, Oostenbrink R, Legerstee JS.

J Autism Dev Disord. 2018 Jul;48(7):2278-2285. doi: 10.1007/s10803-018-3478-0.

11.

Emotional and behavioral problems in children and adolescents with neurofibromatosis type 1.

Rietman AB, van der Vaart T, Plasschaert E, Nicholson BA, Oostenbrink R, Krab LC, Descheemaeker MJ, Wit MY, Moll HA, Legius E, Nijs PFA.

Am J Med Genet B Neuropsychiatr Genet. 2018 Apr;177(3):319-328. doi: 10.1002/ajmg.b.32612. Epub 2017 Dec 15.

PMID:
29243874
12.

Risk Factors of Impaired Neuropsychologic Outcome in School-Aged Survivors of Neonatal Critical Illness.

Leeuwen L, Schiller RM, Rietman AB, van Rosmalen J, Wildschut ED, Houmes RJM, Tibboel D, IJsselstijn H.

Crit Care Med. 2018 Mar;46(3):401-410. doi: 10.1097/CCM.0000000000002869.

PMID:
29194146
13.

Neurobiologic Correlates of Attention and Memory Deficits Following Critical Illness in Early Life.

Schiller RM, IJsselstijn H, Madderom MJ, Rietman AB, Smits M, van Heijst AFJ, Tibboel D, White T, Muetzel RL.

Crit Care Med. 2017 Oct;45(10):1742-1750. doi: 10.1097/CCM.0000000000002553.

PMID:
28650950
14.

Development of emotional and behavioral problems in neurofibromatosis type 1 during young childhood.

Rietman AB, Oostenbrink R, van Noort K, Franken MJP, Catsman-Berrevoets CE, Aarsen FK, Hendriksen JG, de Nijs PFA.

Am J Med Genet A. 2017 Sep;173(9):2373-2380. doi: 10.1002/ajmg.a.38323. Epub 2017 Jun 19.

PMID:
28627810
15.

Motor problems in children with neurofibromatosis type 1.

Rietman AB, Oostenbrink R, Bongers S, Gaukema E, van Abeelen S, Hendriksen JG, Looman CWN, de Nijs PFA, de Wit MC.

J Neurodev Disord. 2017 May 19;9:19. doi: 10.1186/s11689-017-9198-5. eCollection 2017.

16.

Sirolimus for epilepsy in children with tuberous sclerosis complex: A randomized controlled trial.

Overwater IE, Rietman AB, Bindels-de Heus K, Looman CW, Rizopoulos D, Sibindi TM, Cherian PJ, Jansen FE, Moll HA, Elgersma Y, de Wit MC.

Neurology. 2016 Sep 6;87(10):1011-8. doi: 10.1212/WNL.0000000000003077. Epub 2016 Aug 10.

PMID:
27511181
17.

Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

Walsh KS, Janusz J, Wolters PL, Moll HA, van der Vaart T, Rietman AB.

Neurology. 2016 May 10;86(19):1849-50. doi: 10.1212/WNL.0000000000002687. No abstract available.

PMID:
27164720
18.

Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1.

van der Vaart T, Rietman AB, Plasschaert E, Legius E, Elgersma Y, Moll HA; NF1-SIMCODA Study Group.

Neurology. 2016 Jan 12;86(2):154-60. doi: 10.1212/WNL.0000000000002118. Epub 2015 Oct 30.

19.

Epilepsy in children with tuberous sclerosis complex: Chance of remission and response to antiepileptic drugs.

Overwater IE, Bindels-de Heus K, Rietman AB, Ten Hoopen LW, Vergouwe Y, Moll HA, de Wit MC.

Epilepsia. 2015 Aug;56(8):1239-45. doi: 10.1111/epi.13050. Epub 2015 Jun 4.

20.

Treatment of intractable epilepsy in tuberous sclerosis complex with everolimus is not yet evidence-based.

Overwater IE, Rietman AB, Elgersma Y, de Wit MC.

Ann Neurol. 2014 Jan;75(1):163-4. doi: 10.1002/ana.24047. Epub 2014 Jan 2. No abstract available.

PMID:
24243580
21.

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.

van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels A, de Wit MC, Descheemaeker MJ, Vergouwe Y, Catsman-Berrevoets CE, Legius E, Elgersma Y, Moll HA.

Lancet Neurol. 2013 Nov;12(11):1076-83. doi: 10.1016/S1474-4422(13)70227-8. Epub 2013 Oct 1.

PMID:
24090588
22.

Children with specific language impairment show difficulties in sensory modulation.

Taal MN, Rietman AB, Meulen SV, Schipper M, Dejonckere PH.

Logoped Phoniatr Vocol. 2013 Jul;38(2):70-8. doi: 10.3109/14015439.2012.687760. Epub 2012 May 21.

PMID:
22612473

Supplemental Content

Loading ...
Support Center